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Background: Metabolic syndrome (MetS) is related with left ventricular diastolic dysfunction (LVDD) and poor
cardiovascular outcome. Epicardial adipose tissue (EAT) thickness, measured by echocardiography, is increased in
subjects with MetS. However, the association of EAT with LV diastolic function has not been evaluated in subjects
with MetS.
Methods: In this retrospective study, EAT thickness was measured in 1,486 consecutive asymptomatic patients with
no known heart disease who had transthoracic echocardiography during a self-referred healthcare exam. Subjects
with a history of ischemic heart disease, cardiomyopathy or significant valvular heart disease were excluded. LVDD
was defined as E/e’ ratio ≥ 15. Subjects were grouped into two groups, those with MetS and those without.
Results: MetS was present in 346 subjects. There was no difference in LV systolic function between the two
groups. However compared to patients without MetS, patients with MetS had larger left atrium (LA) size and
higher E/e’ ratio (38 ± 5 versus 35 ± 5 mm for LA and 10.0 ± 3.3 versus 8.7 ± 2.7 for E/e’ ratio in subjects with versus
without MetS both p < 0.001). LVDD was found in 27 (7.8%) subjects with MetS, compared to 30 (2.6%) subjects
without MetS (p < 0.001). In subjects with MetS, EAT was significantly correlated with LVDD, even after adjusting
for other cardiometabolic risk factors such as age, systolic blood pressure, BMI, blood glucose and LDL cholesterol
(OR 1.845, 95% CI 1.153-2.951, p = 0.011).
Conclusion: Greater EAT is found in subjects with MetS. EAT is significantly associated with LVDD in subjects
with MetS, even after adjusting for other risk factors.
Keywords: Epicardial fat, Diastolic function, Metabolic syndromeBackground
Epicardial adipose tissue (EAT) is a type of visceral
adipose tissue (VAT) that surrounds the myocardium
and epicardium. EAT has received much attention
recently due to its metabolically active nature and relation
with several bioactive adipokines [1-4]. Studies have
shown an association between EAT and traditional cardio-
vascular risk factors, coronary atherosclerosis, coronary
artery plaque burden, and major adverse cardiovascular* Correspondence: sychoi9@gmail.com
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reproduction in any medium, provided the orevents [5-7]. In addition to coronary artery disease, EAT is
also correlated with left ventricular (LV) function [8,9].
However, the number of published studies and patients
are both limited.
Increased EAT has been reported in patients with
metabolic syndrome (MetS) [10,11]. MetS is a cluster of
the well-established cardiovascular risk factors, including
insulin resistance, obesity and related dyslipidemia. MetS
is associated with poor cardiovascular outcome due to
the atherogenic potential. The presence of MetS has also
been linked with impaired LV diastolic function [12,13].
The association of EAT with either LV diastolic func-
tion or MetS have been separately studied. Yet, the. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ence of MetS has not been studied in a large, asymptom-
atic population free of known coronary artery disease.
Thus, we aimed to evaluate the correlation between
EAT thickness measured by two dimensional echocardi-
ography and LV diastolic function in a population of
asymptomatic Koreans with MetS.Methods
Study population
In this retrospective study, the study subjects were
recruited from Seoul National University Hospital
Healthcare System Gangnam Center. Among those who
visited our echocardiography lab for a health screening
exam between March 2011 and February 2012, EAT was
measured by transthoracic echocardiography in 1,551
subjects without clinical signs and symptoms of heart
disease. Those with significant valvular heart disease, LV
systolic dysfunction, or cardiomyopathy were excluded
from the analysis. Those without blood tests or whose
clinical data were unavailable were also excluded from
the analysis. In total, 1,486 asymptomatic subjects with
EAT measured by echocardiography were included in
this study. Past medical history and current medications
were derived from self-reported medical questionnaires.Measurement of anthropometric parameters
All measurements were performed on the same day as
the echocardiography. Height, body weight, waist cir-
cumference and blood pressure were measured. Waist
circumference was measured in centimeters using the
minimum circumference between the lower rib margin
and the iliac crest in the standing position. Blood pres-
sure was measured for three times in all patients with at
least a 5 minutes interval between measures. Obesity
was defined as a body mass index (BMI) ≥25 kg/m2 [14],
according to the modified WHO criteria from the Asia-
Pacific guideline. Fasting blood glucose level, glycated
hemoglobin, total cholesterol, triglyceride (TG), high
density-lipoprotein (HDL) cholesterol, and low-density
lipoprotein (LDL) cholesterol were measured after at
least 12 hours of fasting in all patients.
MetS was classified according to the recommendations
of National Cholesterol Education Program Adult Treat-
ment Panel III [15]. Blood pressure ≥ 130/85 mmHg or the
subjects’ self-reported history of hypertension or antihyper-
tensive medications, a waist circumference ≥ 90 cm in men
or ≥85 cm in women, triglyceride ≥ 150 mg/dL, HDL
cholesterol ≤ 40 mg/dL in men and ≤50 mg/dL in women,
fasting blood glucose level ≥ 100 mg/dL or a self-reported
history of diabetes or use of diabetes medications were the
parameters included to define MetS. When any three of
the criteria met, the patient was defined as having MetS.Echocardiographic study
All study subjects underwent transthoracic echocardiog-
raphy. Using commercially available equipment (Vivid 7,
GE Medical Systems, Milwaukee, WI), an echocardiogram
was performed by standard technique with subjects in the
left lateral decubitus position. From the two-dimensional
parasternal long axis view, epicardial fat was identified as
the echo-free space between the outer wall of the myo-
cardium and the visceral layer of the pericardium, and was
measured perpendicularly on the right ventricular free
wall at end-diastole [16].
Routine standard echocardiography exam parameters
included LV end-diastolic and end-systolic dimensions,
LV end-diastolic wall thickness, LV ejection fraction,
pulsed-wave Doppler examination of the mitral inflow,
and pulsed-wave tissue Doppler imaging at the medial
mitral annulus. From the mitral inflow Doppler signals,
early transmitral inflow velocity (E), late transmitral
inflow velocity (A), and deceleration time (DT) of E
velocity were obtained with the sample volume placed
between the tips of mitral leaflets. Pulsed-wave tissue
Doppler imaging-derived annular peak velocities (e’ and s’)
were measured, and the ratio of mitral E peak velocity and
e’ peak velocity (E/e’) was calculated. For assessment of LV
diastolic function, E/e’ ratio was used, and subjects with
E/e’ ≥ 15 were defined as having LV diastolic dysfunction
(LVDD).
Statistical analysis
Data are expressed as the mean ± standard deviation or
frequency. Categorical variables were compared using chi-
square analysis and continuous variables were compared
using an unpaired Student’s t-test. To evaluate the cor-
relation of the continuous parameters with LV diastolic
function, bivariate correlation analysis with Pearson’s
correlations was performed. To evaluate the correlation of
various parameters with the presence of LVDD, regression
analysis was performed. Using multiple regression analysis,
other possible confounding covariables were adjusted. For
all statistical analyses, statistical software package (IBM
SPSS statistics 19.0) was used and a p < 0.05 was consid-
ered significant.
Study ethics
The study protocol was reviewed and approved by the
Institutional Review Board of Seoul National University
Hospital (IRB No 1008-036-326). Because the current
study was performed as a retrospective study using the
database and medical records, informed consent was
waived by the board.
Results
The baseline characteristics are shown in Table 1. The
mean age of the study population was 53 ± 9 years old, and
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diastolic blood pressures were 117 ± 13 mmHg and 77 ±
10 mmHg, respectively. The mean BMI was 24 ± 3 kg/m2
in the overall population. According to the criteria as
described above, 346 subjects were defined as having MetS,
and 1,140 subjects did not have MetS. The mean EAT was
2.7 ± 0.8 mm in the overall population. The mean LV
ejection fraction was 66 ± 6% and the mean LA size was
40 ± 5 mm. LVDD was present in 57 (3.8%) subjects.
Clinical and imaging parameters in subjects with and
without MetS
The comparison analyses of the clinical and echocar-
diographic parameters are shown in Table 1. Among
subjects with MetS, 267 (77.2%) were male, compared
to 728 (63.9%) males in the population without MetS.
The mean age, waist circumference and BMI wereTable 1 Baseline characteristics
Parameter Total
n = 1456
Subjects with metabolic s
n = 346
Male, n (%) 995 (67.0%) 267 (77.2%)
Age, yrs 53 ± 9 55 ± 10
SBP, mmHg 117 ± 13 125 ± 13
DBP, mmHg 77 ± 10 82 ± 10
PP, mmHg 40 ± 9 43 ± 10
BMI, kg/m2 24 ± 3 26 ± 3
WC, cm 87 ± 8 93 ± 6
Glucose, mg/dL 101 ± 21 116 ± 32
T. cholesterol, mg/dL 196 ± 33 198 ± 38
Triglyceride, mg/dL 120 ± 81 188 ± 115
HDL cholesterol, mg/dL 51 ± 11 45 ± 9
LDL cholesterol, mg/dL 124 ± 29 126 ± 31
hsCRP, mg/dL 0.15 ± 0.39 0.17 ± 0.32
HbA1C, % 5.7 ± 0.7 6.1 ± 1.0
Echocardiography
EAT, mm 2.7 ± 0.8 2.9 ± 0.9
LVIDd, mm 49 ± 4 50 ± 3
LVIDs, mm 28 ± 3 29 ± 3
LVEF,% 66 ± 6 66 ± 6
LA, mm 40 ± 5 38 ± 5
E 0.59 ± 0.18 0.58 ± 0.27
A 0.60 ± 0.25 0.65 ± 0.43
DT 191 ± 60 198 ± 65
E/A 1.0 ± 0.4 0.9 ± 0.3
E/E’ 9.0 ± 2.9 10.0 ± 3.3
E/E’ ≥ 15 57 (3.8%) 27 (7.8%)
BMI; body mass index, DT; deceleration time, DBP; diastolic blood pressure, EAT; ep
lipoprotein, hsCRP; high-sensitivity C-reactive protein, LA; left atrium size, LVIDd; lef
left ventricular systolic dimension, LDL; low-density lipoprotein, PP; pulse pressure,significantly higher in subjects with MetS (all p <
0.001). The systolic and diastolic blood pressure, fast-
ing glucose level, glycated hemoglobin level and TG
were significantly higher in the subjects with MetS
(all p < 0.001).
The echocardiographic parameters showed no dif-
ference in LV systolic function between the two groups
(p = 0.526). The mean EAT was greater in subjects with
MetS compared to those without MetS (2.9 ± 0.9 versus
(vs) 2.7 ± 0.8 mm in subjects with vs. without MetS,
p < 0.001, Figure 1). Both a larger LA size and a
higher E/e’ ratio were found in subjects with MetS
versus those without MetS (38 ± 5 vs. 35 ± 5 mm and
10.0 ± 3.3 vs. 8.7 ± 2.7, respectively, both p < 0.001,
Figure 2). LVDD was found in 27 (7.8%) subjects with
MetS, compared to 30 (2.6%) subjects without MetS




53 ± 9 <0.001
115 ± 12 <0.001
75 ± 9 <0.001
40 ± 9 <0.001
23 ± 3 <0.001
85 ± 7 <0.001
97 ± 14 <0.001
195 ± 32 0.157
100 ± 52 <0.001
53 ± 11 <0.001
123 ± 29 0.101
0.14 ± 0.41 0.200
5.6 ± 0.5 <0.001
2.7 ± 0.8 <0.001
48 ± 4 <0.001
28 ± 3 <0.001
66 ± 6 0.526
35 ± 5 <0.001
0.60 ± 0.14 0.104
0.59 ± 0.16 0.004
189 ± 58 0.014
1.1 ± 0.4 <0.001
8.7 ± 2.7 <0.001
30 (2.6%) <0.001
icardial adipose tissue, HbA1C; glycated hemoglobin, HDL; high-density
t ventricular diastolic dimension, LVEF; left ventricular ejection fraction, LVIDs;
SBP; systolic blood pressure, T.chol; total cholesterol, WC; waist circumference.
Figure 1 Epicardial fat thickness in subjects with versus
without metabolic syndrome (Abbreviations: EAT = epicardial
adipose tissue, MetS =metabolic syndrome).










Age 0.412 <0.001 0.447 <0.001
SBP 0.296 <0.001 0.194 <0.001
DBP 0.032 0.548 0.078 0.008
PP 0.345 <0.001 0.194 <0.001
BMI 0.027 0.620 0.188 <0.001
WC −0.034 0.527 0.181 <0.001
Glucose 0.089 0.098 0.165 <0.001
HbA1C 0.155 0.004 0.146 <0.001
T. cholesterol −0.087 0.107 −0.014 0.629
Triglyceride −0.017 0.757 0.026 0.381
HDL cholesterol 0.032 0.547 0.019 0.514
LDL cholesterol −0.112 0.038 −0.036 0.228
hsCRP −0.070 0.277 0.072 0.053
EAT by TTE 0.142 0.008 0.041 0.166
LVEF 0.080 0.137 0.046 0.120
LA size 0.266 <0.001 0.273 <0.001
BMI; body mass index, DBP; diastolic blood pressure, EAT; epicardial adipose
tissue, HbA1C; glycated hemoglobin, HDL; high-density lipoprotein, hsCRP;
high-sensitivity C-reactive protein, LA; left atrium, LVEF; left ventricular ejection
fraction, LDL; low-density lipoprotein, PP; pulse pressure, SBP; systolic blood
pressure, T.chol; total cholesterol, TTE; transthoracic echocardiography, WC;
waist circumference.
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diastolic function
Bivariate analysis was performed to evaluate the associ-
ation of various parameters with LV diastolic function
(Table 2). In subjects with MetS, LV diastolic function
as assessed by E/e’ ratio was significantly associated
with age (r = 0.412, p < 0.001), systolic blood pressure
(r = 0.296, p < 0.001), glycated hemoglobin level (r = 0.155,
p = 0.004), LDL cholesterol (r = −0.112, p = 0.038), LA size
(r = 0.266, p < 0.001) and EAT (r = 0.142, p = 0.008).
In subjects without MetS, age (r = 0.447, p < 0.001),
systolic blood pressure (r = 0.194, p < 0.001). diastolic
blood pressure (r = 0.078, p = 0.008), BMI (r = 0.188,
p < 0.001), waist circumference (r = 0.181, p < 0.001),
glucose (r = 0.165, p < 0.001), glycated hemoglobinFigure 2 Left ventricular diastolic function in subjects with versus
without metabolic syndrome (Abbreviations: MetS =metabolic
syndrome).(r = 0.146, p < 0.001), and LA size (r = 0.273, p < 0.001)
showed correlation with E/e’ ratio.
Multivariate analysis showing parameters associated with
LVDD
The univariate analysis showed positive correlation be-
tween EAT and LVDD in subjects with MetS (OR 1.946,
95% confidence interval 1.308-2.896, p = 0.001), whereas
in subjects without MetS, EAT did not show significant
correlation with LVDD (p = 0.453).
To adjust other possible confounding variables, multi-
variate regression analysis was performed including age,
systolic blood pressure, BMI, glucose and LDL choles-
terol, as shown in Table 3. After adjusting for the covari-
ables, EAT was still significantly associated with LVDD
in subjects with MetS (OR 1.845, 95% CI 1.153-2.951,
p = 0.011), whereas in subjects without MetS, such
correlation was not found (p = 0.101).
Discussion
In this study we aimed to assess the association of EAT
thickness with LVDD in subjects with MetS. Using two-
dimensional echocardiography we demonstrated that
EAT thickness is significantly associated with LVDD in
subjects with MetS, and this association remains after
Table 3 Multivariate analysis showing parameters
associated with LV diastolic function





EAT by echocardiography, mm 1.845 1.153-2.951 0.011
Age, years 1.090 1.037-1.146 0.001
SBP, mmHg 1.034 1.000-1.069 0.051
BMI, kg/m2 1.002 0.832-1.206 0.986
Glucose, mg/dL 1.001 0.987-1.015 0.921
LDL cholesterol, mg/dL 0.999 0.985-1.013 0.847
Patients without metabolic
syndrome
EAT by echocardiography, mm 0.667 0.411-1.082 0.101
Age, years 1.105 1.057-1.154 <0.001
SBP, mmHg 1.037 1.007-1.068 0.015
BMI, kg/m2 1.175 1.006-1.371 0.041
Glucose, mg/dL 1.017 0.998-1.037 0.085
LDL cholesterol, mg/dL 0.993 0.979-1.007 0.302
BMI; body mass index, EAT; epicardial adipose tissue, LDL; low-density lipopro-
tein, SBP; systolic blood pressure
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glucose level, and LDL cholesterol. Importantly, we did
not observe this association in subjects without MetS.
The echocardiographic measurement of EAT was
proposed and validated by Iacobellis et al. [17,18].
Several studies have assessed epicardial fat using cor-
onary CT or cardiac magnetic resonance imaging
(MRI). However, measuring EAT by echocardiography
has several advantages over CT or MRI. It is inexpen-
sive, easier to access, and rapidly applicable especially
within clinical practice, and has high reproducibility.
Moreover, when compared to CT, echocardiography is
radiation-free and free from contrast agent-related
side effects. Considering these significant advantages
and placed within the context of the current study
population, which consisted of subjects without clin-
ical signs or symptoms of heart disease who were
self-referred for health exams, the data strongly sug-
gests that the echocardiographic measurement of EAT
is preferred to CT.
We found that EAT thickness was greater in sub-
jects with MetS, consistent with previous studies
[10,11,19]. Our data indicate that EAT thickness is as-
sociated with metabolic factors and is correlated with
the main anthropometric and clinical parameters of
metabolic syndrome [10,20,21]. This data is consistent
with a previous study that reported EAT thickness
increases with an increasing number of MetS compo-
nents [11].MetS is a cluster of several cardiometabolic risk factors
and is eventually associated with cardiovascular disease.
Visceral obesity and insulin resistance have been
proposed as the main underlying mechanism. Both are
strongly linked with hypertension, dyslipidemia and ath-
erosclerotic coronary artery disease. In current study, we
assessed functional aspect of myocardium rather than
vascular disease. To avoid other possible confounding
factors, we adjusted cardiometabolic risk factors using
multivariate regression model. Our result still showed
significant association between EAT and LV diastolic
function in presence of MetS. Although the underlying
mechanism is not fully understood yet, increased EAT,
measured by either CT or echocardiography, has con-
sistently shown independent correlation with impaired
diastolic function. Cavalcante et al. reported that
epicardial fat volume is an independent correlate of
impaired diastolic function after accounting for asso-
ciated comorbidities [9]. They studied 110 apparently
healthy individuals, and found that epicardial fat
volume adds increment predictive value for diastolic
dysfunction.
Having similar properties and origin with visceral adi-
pose tissue, EAT has been suggested as an active organ
producing several proinflammatory and proatherogenic
bioactive cytokines [22-24]. Also with its anatomic prox-
imity to the heart without fascial protection inbetween,
the possible local interaction via paracrine or vasocrine
effect was suggested as a mechanism that causes coron-
ary artery disease or LVDD [1,3,25,26].
As shown in our study, EAT thickness was independ-
ently associated with LVDD in subjects with MetS.
LVDD is clinically significant and related to poor out-
come. This was demonstrated in the longitudinal study
of Olmsted County, in which increased all-cause mortal-
ity was significantly associated with presence of LVDD
[27]. The significance was still present after adjusting for
age, gender and ejection fraction.
Limitations
There are several limitations in our study. First, the
measurement of epicardial fat tissue by echocardiog-
raphy can vary depending on the experience of the car-
diologist. To minimize such inter- and intra-observer
variability, we repeatedly compared images and had dis-
cussions among cardiologists in our center. From these
group discussions an overall consensus was drawn on
the interpretation of the images. Also, our cardiologists
are all well-trained individuals with much experience in
echocardiography. Second, since the study is performed
as a cross-sectional study, we do not have clinical out-
come data. Third, assessing additional biomarkers may
help strengthen our findings and aid in the interpret-
ation of our results.
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EAT thickness measured by echocardiography is inde-
pendently associated with LV diastolic function in sub-
jects with MetS. This correlation remained significant
after adjusting for other known cardiometabolic risk
factors, such as age, systolic blood pressure, BMI, blood
glucose and LDL cholesterol.
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